Aclaris Therapeutics, Inc. (0H8T)

Overview

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel treatments for immune-inflammatory diseases. The company, founded in 2012 and based in Wayne, Pennsylvania, operates within the United States across two main segments: Therapeutics and Contract Research. The Therapeutics segment is focused on identifying and developing innovative therapies aimed at meeting the significant unmet needs in immuno-inflammatory diseases. Meanwhile, the Contract Research segment offers laboratory services, supporting the broader research and development efforts within the field.

Products and Services

• Zunsemetinib (ATI-450)

  An MK2 inhibitor currently under Phase 1b/2 trials designed for the treatment of metastatic breast and pancreatic cancer. Zunsemetinib aims to address critical gaps in the treatment of these widespread and deadly cancers by targeting and inhibiting specific molecular pathways associated with tumor growth and spread.

• ATI-1777

  A soft JAK 1/3 inhibitor that has completed Phase 2b trials for the treatment of moderate to severe atopic dermatitis, among other dermatologic conditions. ATI-1777 represents a novel approach in managing dermatologic conditions by modulating the immune response, potentially offering a therapeutic alternative for patients with limited treatment options.

• ATI-2138

  An oral covalent inhibitor of ITK and JAK3, currently under Phase 1 trials as a potential treatment for T cell-mediated autoimmune diseases. ATI-2138 works by inhibiting specific enzymes involved in the activation of T cells, part of the immune system's response that can cause harmful inflammation in autoimmune diseases.